Background Combination antimalarial therapy is recommended for the treatment of
uncomplicated falciparum malaria in Africa; however, some concerns about the safety and …

The study aimed to characterize the population pharmacokinetics of amodiaquine (AQ) and
its major metabolite N-desethylamodiaquine (N-DEAQ), and to assess the correlation …

Background Artesunate+ amodiaquine (AS+ AQ) and artemether-lumefantrine (AL) are now
the most frequently recommended first line treatments for uncomplicated malaria in Africa …

Background Numerous trials have demonstrated high efficacy and safety of artemisinin-
based combination therapy (ACT) under supervised treatment. In contrast, effectiveness …

Background Combination therapies are now recommended to treat uncomplicated malaria.
We used a longitudinal design to assess the incidence of malaria and compare the …

Background Malaria and HIV infections are both highly prevalent in sub-Saharan Africa, with
HIV-infected patients being at higher risks of acquiring malaria. The majority of antiretroviral …

Two years after the introduction of free Artesunate‐Amodiaquine (ASAQ) and Artemether‐
Lumefantrine (AL) for the treatment of uncomplicated malaria in public health facilities in …

The World Health Organization strongly recommends artemisinin-based combination
therapy (ACT) regimens for the treatment of uncomplicated Plasmodium falciparum malaria …

Background One promising new Artemisinin-based combination therapies (ACTs) is
dihydroartemisinin-piperaquine (DHA-PQ). However, the pharmacokinetics of piperaquine …

Background Artemisinin-based combination therapy (ACT) and novel drug combinations are
available and used in African countries to treat uncomplicated malaria. Network meta …